Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Viking Therapeutics (VKTX) vs. Competitors

7,764 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
VKTXViking Therapeutics$25.84$3.30B-4.79-28.30%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumVKTXUnlock the VKTX top-analyst price target with TipRanks Premium
NAMSNewAmsterdam Pharma Company$19.51$2.34B-11.41-49.48%Strong BuyUnlock the NAMS analyst price target with TipRanks PremiumVKTX vs NAMSUnlock the NAMS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$14.16$1.25B-3.25-66.38%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumVKTX vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$17.12$1.22B-4.39-53.11%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumVKTX vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.58$1.50B-3.82-55.46%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumVKTX vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium
PBLSParabilis Medicines, Inc.$27.63$3.46B-14.85-12.58%Strong BuyUnlock the PBLS analyst price target with TipRanks PremiumVKTX vs PBLSUnlock the PBLS top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
VKTXViking Therapeutics25.84-8.43-24.60%
NAMSNewAmsterdam Pharma Company19.51-18.20-48.26%
MLYSMineralys Therapeutics, Inc.14.16-27.71-66.18%
GPCRStructure Therapeutics, Inc. Sponsored ADR17.12-17.22-50.15%
KLRAKailera Therapeutics, Inc.11.58-14.42-55.46%
PBLSParabilis Medicines, Inc.27.63-3.98-12.58%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts